GlaxoSmithKline Share Price Soars 36% in 2 Days After Strong Q3 FY25 Results

GlaxoSmithKline (GSK) shares surged by over 17% on February 18, extending a 3-day rally. The stock jumped as much as 17.69% to ₹2,744.95 per share on the BSE. This comes after the company reported impressive growth in its Q3 FY25 earnings, which fueled investor optimism.

Strong Q3 FY25 Performance Drives Rally 

GSK Pharmaceuticals announced a remarkable 400% increase in its net profit for Q3FY25, reaching ₹230 crore, compared to ₹46 crore in the same quarter previous year. The company’s revenue grew by 18% to ₹949.42 crore, up from ₹805.26 crore YoY.

EBITDA also saw a outstanding boost, rising by 33.8% to ₹291.9 crore, and the EBITDA margin expanded to 30.7%, up from 27.1% YoY.

Key Drivers of Growth 

GSK’s general medicines portfolio, including popular brands like Augmentin, Ceftum, and T-bact, saw market share gains. The company’s Respiratory portfolio, led by Nucala and Trelegy, also experienced strong growth, increasing patient access across India.

In the vaccines segment, GSK maintained its leadership in the self-pay private market for pediatric vaccines and gained momentum in adult immunisation with the Shingrix vaccine.

Stock Performance and Market Outlook 

Over the past month, GSK’s stock price has surged by 27%, and it has gained more than 17% year-to-date. Despite a 10% dip in the past 6 months, the stock has risen 16% over the last year. Over the past 2 years, it has delivered an impressive return of over 110%.

As of 2:20 PM, GSK shares were trading 7.92% higher at ₹2,516.95 per share on the BSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.